[Clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a therapy]. [electronic resource]
Producer: 20190325Description: 583-588 p. digitalISSN:- 1007-3418
- Antiviral Agents -- therapeutic use
- DNA, Viral -- drug effects
- Hepatitis B e Antigens -- blood
- Hepatitis B virus -- drug effects
- Hepatitis B, Chronic -- blood
- Humans
- Interferon-alpha
- Polyethylene Glycols -- administration & dosage
- Recombinant Proteins -- administration & dosage
- Seroconversion
- Telbivudine -- therapeutic use
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.